What are the main functions and effects of Cabergoline?

Cabergoline is marketed in many countries and regions around the world under the trade nameDOSTINEX. It is a highly selective dopamine D2 receptor agonist. Its main component is cabergoline. It inhibits the secretion of prolactin by directly acting on the dopamine receptors on the prolactin-secreting cells of the anterior pituitary gland, thereby restoring the endocrine balance in the body. The drug has significant efficacy in the treatment of idiopathic hyperprolactinemia (HPRL) and hyperprolactinemia caused by pituitary adenomas (prolactinomas). Hyperprolactinemia can lead to amenorrhea, galactorrhea, infertility in women, as well as decreased sexual function and sperm quality in men. Long-term high levels of prolactin may also affect bone density and metabolic function. By reducing prolactin levels, cabergoline can restore normal menstrual cycles, improve ovulatory function, increase chances of conception, and improve testosterone levels and sexual function in men.

Another major feature of DOSTINEX is its long half-life, which usually only needs to be taken once or twice a week to maintain a stable inhibitory effect, which has advantages in terms of patient compliance. Compared with traditional bromocriptine, cabergoline is better tolerated, has milder gastrointestinal reactions, and its inhibitory effect on prolactin is more durable and stable. In the treatment of pituitary microadenomas and some macroadenomas, long-term use of cabergoline can not only effectively control serum prolactin levels, but may also promote tumor size reduction, thereby alleviating symptoms caused by tumor compression of the optic chiasm or adjacent brain structures.

Overseas clinical applications also show that cabergoline can help improve motor symptoms as a dopamine receptor agonist in some treatment options for Parkinson's disease. However, the approval status of this indication varies in different countries, and the dosage and course of treatment are also different. In the treatment of hyperprolactinemia, a decrease in serum prolactin is often seen at the initial dose of the drug, and some patients can experience symptom improvement within a few weeks. For patients with tumors, imaging evaluation can also observe a shrinkage of lesions after several months.

Since cabergoline has not yet been officially launched as an original drug in mainland China, DOSTINEX’s drug purchase channels mainly rely on overseas regular pharmacies or cross-border medical services. When choosing a purchasing channel, you must ensure that the source of drugs is formal and avoid safety risks caused by counterfeit or inferior drugs. This drug is a prescription drug, and patients should take it under the guidance of a doctor and regularly monitor prolactin levels, imaging examinations, and cardiac ultrasound evaluations, especially for patients who require long-term treatment.

In general, cabergoline (DOSTINEX) can not only effectively reduce prolactin levels and restore endocrine and reproductive functions in the treatment of hyperprolactinemia, but can also improve a variety of clinical symptoms caused by pituitary adenomas. Its long-lasting effect and good tolerability make it an internationally recognized first-line treatment drug. Reasonable selection of dosage and monitoring of efficacy and side effects are the keys to ensuring that the drug maximizes benefits and reduces risks.

Reference materials:https://www.drugs.com/mtm/cabergoline.html